Gilead And Kite Oncology Present Data Demonstrating Car T-cell Therapy Survival Benefit And Showcasing Latest Advances In Blood Cancer Portfolio At ASH 2023
Portfolio Pulse from Benzinga Newsdesk
Gilead and Kite Oncology have presented data at ASH 2023 demonstrating the survival benefits of their CAR T-cell therapy and showcasing the latest advances in their blood cancer portfolio. The data includes longer follow-up analyses of survival data showing the curative intent of Yescarta across different lines of therapy and age groups, including 65+. The durability of response and survival with Tecartus in adult relapsed/refractory B-cell acute lymphoblastic leukemia and mantle cell lymphoma was also observed in the largest real-world evidence studies to date.
November 02, 2023 | 1:25 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Gilead's presentation of promising data on their CAR T-cell therapy at ASH 2023 could potentially boost investor confidence and positively impact the company's stock in the short term.
The presentation of positive data on a company's product, especially in a high-profile event like ASH 2023, can often lead to increased investor confidence in the company's potential for success, which can in turn lead to a positive impact on the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100